Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00606632 · ClinicalTrials.gov registry record · Phase 3

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

A Phase 3 study, sponsored by Heidelberg Pharma.

Completed
Registry status
Phase 3
Development phase
226
Enrollment target

NCT00606632: Completed Phase 3 study, sponsored by Heidelberg Pharma.

NCT00606632 is a Phase 3 study that has completed, run by Heidelberg Pharma. The registered enrollment target is 226 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00606632, a Phase 3 study, has completed, sponsored by Heidelberg Pharma.

COMPLETED
Registry status
Phase 3
Development phase
226 participants
Enrollment target

Study Summary

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

Primary Outcome

Average estimate of three independent, blinded central readers per imaging modality on the proportion of participants that were correctly identified on the 124I-cG250 PET/CT Images of having (sensitivity) or not having (specificity) clear cell renal carcinoma (ccRCC) compared to CT images. Histopathology provided the standard-of-truth because it is the only definitive method for accurately identifying ccRCC.

Interventions

  • DRUG 124-Iodine-cG250 (124I-cG250)
  • PROCEDURE CT

Trial Details

FieldValue
Enrollment Target 226 participants
Start Date 2008-03
Est. Completion 2009-12
Phase Phase 3
Heidelberg Pharma

5 total trials

What the finished NCT00606632 record still lists

NCT00606632 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 2 interventions - of which 124-Iodine-cG250 (124I-cG250) is the first listed.

NCT00606632 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00606632 about?

NCT00606632 is a clinical study titled "Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody". This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

What is the current status of trial NCT00606632?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2008-03. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00606632?

The interventions under investigation include: 124-Iodine-cG250 (124I-cG250) (DRUG), CT (PROCEDURE).

Who is sponsoring clinical trial NCT00606632?

This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00606632's enrollment target sits among peer trials

226 1310th of 2000 higher than 690 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04419272 · 226 participants · Phase 4

    Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

  • NCT05449002 · 226 participants · NA

    Digital Single Session Intervention for Youth Mental Health

  • NCT05488054 · 226 participants · NA

    Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery

  • NCT05924477 · 226 participants · NA

    Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00606632, the US trial registry maintained by the National Library of Medicine. NCT00606632 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.